Holen Sie sich die Stockscreener-App
805.52
0.39%
-4.79
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN) - finance.yahoo.com
Regeneron at Wells Fargo healthcare conference: growth broadens By Investing.com - Investing.com UK
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08 - marketscreener.com
Why is Regeneron Pharmaceuticals (NASDAQ:REGN) drawing investor attention today? - Kalkine Media
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock - finance.yahoo.com
Did Libtayo Recall Just Shift Regeneron's (REGN) Investment Narrative? - simplywall.st
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron stock holds firm after strong Q2 2026 results - AD HOC NEWS
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 DeadlineRGRD Law - marketscreener.com
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - The Globe and Mail
1 WEEK REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Re - natlawreview.com
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
Regeneron stock slips on a $85.2 billion market value - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Robbins LLP Urges REGN Investors to Contact the Firm Before - GlobeNewswire
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Biotech Stocks To Watch TodaySeptember 4th - MarketBeat
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment - AD HOC NEWS
Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data - BioCentury
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock steadies after strong Q2 figures and pipeline focus - AD HOC NEWS
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact SueWallSt - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 - Morningstar
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 - Investing.com
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB - Yahoo Finance
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? - Barchart.com
Why Did Regeneron Pharmaceuticals (REGN) Climb After Its Latest Update? - simplywall.st
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline - Eastern Progress
Regeneron stock gains after steady 2026 growth and legal action reminder - AD HOC NEWS
Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
REGN 2-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron stock draws investor interest as class action lawsuit and strong earnings frame the outloo - AD HOC NEWS
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) - The National Law Review
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP - Yahoo Finance
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline - Eastern Progress
Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial - marketscreener.com
REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman - TMX Newsfile
0.22%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):